Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines.
Cancer
Proteomics
Transcriptomics
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
23 Jul 2021
23 Jul 2021
Historique:
received:
09
02
2021
revised:
26
05
2021
accepted:
28
06
2021
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Small-molecule tankyrase 1 and tankyrase 2 (TNKS1/2) inhibitors are effective antitumor agents in selected tumor cell lines and mouse models. Here, we characterized the response signatures and the in-depth mechanisms for the antiproliferative effect of tankyrase inhibition (TNKSi). The TNKS1/2-specific inhibitor G007-LK was used to screen 537 human tumor cell lines and a panel of particularly TNKSi-sensitive tumor cell lines was identified. Transcriptome, proteome, and bioinformatic analyses revealed the overall TNKSi-induced response signatures in the selected panel. TNKSi-mediated inhibition of wingless-type mammary tumor virus integration site/β-catenin, yes-associated protein 1 (YAP), and phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT signaling was validated and correlated with lost expression of the key oncogene MYC and impaired cell growth. Moreover, we show that TNKSi induces accumulation of TNKS1/2-containing β
Identifiants
pubmed: 34337362
doi: 10.1016/j.isci.2021.102807
pii: S2589-0042(21)00775-6
pmc: PMC8313754
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102807Informations de copyright
© 2021 The Authors.
Références
Nat Cell Biol. 2011 May;13(5):623-9
pubmed: 21478859
Nature. 2015 Apr 16;520(7547):307-11
pubmed: 25877200
Cancer Res. 2011 Jan 1;71(1):197-205
pubmed: 21199802
Nat Rev Mol Cell Biol. 2019 Apr;20(4):199-210
pubmed: 30824861
Eur J Med Chem. 2017 Dec 15;142:506-522
pubmed: 29107427
J Biol Chem. 2016 Jul 15;291(29):15256-66
pubmed: 27231341
Nature. 2016 May 18;533(7603):333-7
pubmed: 27193678
Annu Rev Pathol. 2011;6:479-507
pubmed: 21090969
Genes Dev. 2015 Jan 15;29(2):157-70
pubmed: 25547115
Mol Cancer Res. 2018 Mar;16(3):543-553
pubmed: 29222171
J Med Chem. 2020 Jul 9;63(13):6834-6846
pubmed: 32511917
Cancer Lett. 2018 Feb 1;414:1-15
pubmed: 29126913
Cancer Res. 2014 Jun 15;74(12):3294-305
pubmed: 24747911
Cancer Sci. 2018 Dec;109(12):4003-4014
pubmed: 30238564
Genome Res. 2011 Dec;21(12):2213-23
pubmed: 21903743
Cell. 2014 Jul 3;158(1):157-70
pubmed: 24976009
Cancers (Basel). 2020 Jun 19;12(6):
pubmed: 32575464
Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
J Biol Chem. 2002 Apr 19;277(16):14116-26
pubmed: 11854288
Cancer Discov. 2019 Oct;9(10):1358-1371
pubmed: 31337618
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Biochem J. 2014 Apr 15;459(2):275-87
pubmed: 24467442
Bioinformatics. 2016 Oct 1;32(19):3012-4
pubmed: 27288499
J Med Chem. 2013 Aug 22;56(16):6495-511
pubmed: 23844574
Mol Cell. 2016 Aug 4;63(3):498-513
pubmed: 27494558
F1000Res. 2018 Aug 31;7:
pubmed: 30228872
Nature. 2009 Oct 1;461(7264):614-20
pubmed: 19759537
Commun Biol. 2020 Apr 24;3(1):196
pubmed: 32332858
J Med Chem. 2013 Apr 11;56(7):3012-23
pubmed: 23473363
Sci Rep. 2019 Dec 13;9(1):19130
pubmed: 31836723
Mol Cell Proteomics. 2020 Dec;19(12):2015-2030
pubmed: 32958691
Nat Rev Cancer. 2015 Oct;15(10):593-607
pubmed: 26383138
Mol Cell Biol. 2018 Oct 29;38(22):
pubmed: 30181396
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Oncotarget. 2016 May 17;7(20):28765-82
pubmed: 27144834
Nucleic Acids Res. 2019 Jan 8;47(D1):D917-D922
pubmed: 30496479
PLoS One. 2011;6(7):e22595
pubmed: 21799911
Toxicol Pathol. 2016 Feb;44(2):267-78
pubmed: 26692561
Oncol Lett. 2018 Dec;16(6):6895-6902
pubmed: 30546421
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Science. 1998 Nov 20;282(5393):1484-7
pubmed: 9822378
Diabetologia. 2016 Mar;59(3):582-91
pubmed: 26631215
Exp Cell Res. 2020 May 1;390(1):111935
pubmed: 32151493
Cancer Res. 2012 Jun 1;72(11):2822-32
pubmed: 22440753
Cell Rep. 2015 Oct 20;13(3):524-532
pubmed: 26456820
Dev Cell. 2010 Oct 19;19(4):507-20
pubmed: 20951343
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
J Med Chem. 2013 Jun 13;56(11):4320-42
pubmed: 23701517
PLoS One. 2017 Jan 20;12(1):e0170508
pubmed: 28107521
Curr Pharm Des. 2014;20(41):6472-88
pubmed: 24975604
Nat Commun. 2018 Nov 9;9(1):4728
pubmed: 30413706
Mol Cancer Ther. 2017 Apr;16(4):752-762
pubmed: 28179481
Bone. 2018 Jan;106:156-166
pubmed: 29055830
Cancer Res. 2012 Jul 1;72(13):3119-24
pubmed: 22706201
Clin Transl Oncol. 2018 Jul;20(7):827-836
pubmed: 29230693
Nat Commun. 2017 Dec 20;8(1):2214
pubmed: 29263426
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Mol Cancer Res. 2015 Nov;13(11):1487-501
pubmed: 26124443
Nucleic Acids Res. 2015 Dec 2;43(21):e140
pubmed: 26184878
J Med Chem. 2017 Dec 28;60(24):10013-10025
pubmed: 29155568
Cancer Res. 2013 May 15;73(10):3132-44
pubmed: 23539443
Clin Cancer Res. 2016 Feb 1;22(3):644-56
pubmed: 26224873
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Oncogenesis. 2016 Apr 18;5:e220
pubmed: 27089143
Science. 1998 Sep 4;281(5382):1509-12
pubmed: 9727977
Cells. 2019 Jun 17;8(6):
pubmed: 31212916
Nat Commun. 2019 Sep 25;10(1):4363
pubmed: 31554794
ACS Med Chem Lett. 2015 Jan 13;6(3):254-9
pubmed: 25815142
PLoS Biol. 2003 Oct;1(1):E10
pubmed: 14551908
J Biol Chem. 2004 Sep 24;279(39):40255-8
pubmed: 15304487
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Int J Obes (Lond). 2020 Aug;44(8):1691-1702
pubmed: 32317752